Danh sách các công bố nghiên cứu lâm sàng về hiệu quả của Bào tử lợi khuẩn LiveSpo
1. LiveSpo® NAVAX’s report on Nature.com 2025
Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial
2. LiveSpo® CLAUSY’s report on Nature.com 2024
3. LiveSpo® PREG-MOM & LiveSpo® KIDS on Clinicaltrials.gov, NIH US, 2024
3. LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2024
4. LiveSpo® DIA30 on the ClinicalTrials.gov - U.S. National Library of Medicine
5. LiveSpo® X-Secret on Clinicaltrials.gov, NIH US, 2024
Effects of LiveSpo® X-SECRET in supportive treatment of vaginitis.
6. LiveSpo® NAVAX’s report on Nature.com 2023
Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal spraying Bacillus spore probiotics
7. LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2023
LiveSpo® NAVAX supports the treatment of acute Rhinosinusitis and Otitis media
8. LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2023
9. LiveSpo® NAVAX’s report on Nature.com 2022
Nasal-spraying Bacillus spores as an effective symptomatic treatment for children with acute respiratory syncytial virus infection; Scientific Reports (2022) 12:12402, DOI: 10.1038/s41598-022-16136-z.
10. American Society for Microbiology, Washington DC, 2022
11. American Society for Microbiology, Washington DC, 2022
12. LiveSpo® NAVAX on the ClinicalTrials.gov - U.S. National Library of Medicine.
13. LiveSpo® NAVAX on Clinicaltrials.gov, NIH US, 2022
Effects of nasal-spraying LiveSpo® NAVAX in treatment of Influenza virus in children.
14. LiveSpo’s report on National Library of Medicine, USA
15. FDA NDI 1167 for LiveSpo® COLON.
Bacillus clausii and Bacillus subtilis, under tradename LiveSpo® COLON - Ana Bio Research & Development JSC - 10/15/2020. Letter from FDA CFSAN to Ana Bio Research & Development JSC regarding NDI 1167 - LiveSpo ® COLON
https://www.regulations.gov/search?filter=ndi%201167